Targeted Pulse Quiz: October 6

Durcabtagene autoleucel shows high response rates in R/R multiple myeloma; olomorasib plus pembrolizumab demonstrates efficacy in KRAS G12C-mutated NSCLC; and the combination of talquetamab, daratumumab, and pomalidomide achieves durable responses. We also cover the FDA’s ODAC vote against checkpoint inhibitors for esophageal cancer.

In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, discusses the background, findings, and implications of the phase 3 EMERALD trial.

HBI0101, an academically sourced CAR T-cell therapy, demonstrated a high objective response rate and manageable safety in patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic testing in the breast cancer space.

For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.